title: [Anesthesia for electroconvulsive therapy: clinical experience].
abstract: OBJECTIVE
  To assess the utility of propofol and succinylcholine in obtaining optimal convulsions and assuring patient safety during electroconvulsive therapy.
  
  
  METHODS
  This was a prospective observational study of patients undergoing electroconvulsive therapy under general anesthesia with propofol and succinylcholine. We recorded patient characteristics, doses of propofol and succinylcholine, electroencephalographically-recorded duration of convulsions, and complications. Descriptive statistics were compiled and the data were subjected to analysis of correlations, comparison with the Student t test for independent samples, the Mann-Whitney U test, and analysis of variance.
  
  
  RESULTS
  We studied 108 patients, 62% women and 38% men, 80% classified as ASA 1 and 20% as ASA 2. The patients underwent 844 sessions of electroconvulsive therapy; their mean (SD) age was 39.95 (18.09) years. The doses of propofol and succinylcholine were 1.34 (0.32) mgxkg(-1) and 1.35 (0.26) mgxkg(-1), respectively. The mean recorded duration of the first convulsion (29.87 [22.42] seconds) was negatively correlated with age (r = -0.12) and unrelated to propofol dose (r = 0.06) or body weight (r = 0.02). Male and schizophrenic patients had longer-lasting convulsions (P < .01). Cardiovascular complications occurred in 2.4% and psychomotor agitation in 1.4%; there were no respiratory complications, musculoskeletal injuries, nausea, or vomiting.
  
  
  CONCLUSIONS
  Electroconvulsive therapy can be safely applied in an operating room or similar space undergeneral anesthesia and with a neuromuscular blockade in order to prevent psychological or musculoskeletal trauma. Propofol did not affect the convulsions at the dosages administered.
authors.affiliation: Departamento de Anestesiología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. gonzalea@med.puc.cl
authors.forename: A G
authors.initials: AG
authors.lastname: González
authors.forename: L I
authors.initials: LI
authors.lastname: Cortínez
authors.forename: J C
authors.initials: JC
authors.lastname: De la Cuadra
authors.forename: E
authors.initials: E
authors.lastname: Carrasco
authors.forename: A
authors.initials: A
authors.lastname: Rioseco
authors.forename: P
authors.initials: P
authors.lastname: Léniz
mesh_terms: D000328:Adult; D000768:Anesthesia, General; D000771:Anesthesia, Intravenous; D018686:Anesthetics, Intravenous / Q000008:administration & dosage*; D004565:Electroconvulsive Therapy / Q000009:adverse effects; D004569:Electroencephalography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000209:etiology; D008297:Male; D009325:Nausea / Q000517:prevention & control; D009467:Neuromuscular Depolarizing Agents / Q000008:administration & dosage*; D015742:Propofol / Q000008:administration & dosage*; D011446:Prospective Studies; D011595:Psychomotor Agitation / Q000209:etiology; D013390:Succinylcholine / Q000008:administration & dosage*
chemical_list: D018686:Anesthetics, Intravenous; D009467:Neuromuscular Depolarizing Agents; D013390:Succinylcholine; D015742:Propofol